Pharmanutra the Stock: price and directors' dealings · Italy · Consob

About Pharmanutra the

PharmaNutra S.p.A. is an Italian listed company traded on Borsa Italiana (FTSE MIB), with its stock specifically associated with the Euronext STAR Milan segment in Italy. Founded in 2003 by brothers Andrea and Roberto Lacorte, the company has built a reputation as a science-driven developer, manufacturer and marketer of mineral-based food supplements and medical devices focused on muscles, joints and specialised nutrition. Its legal headquarters are in Pisa, Italy, and its new headquarters, inaugurated in 2023 in Via Campodavela, forms part of a chemical-pharmaceutical hub designed to strengthen manufacturing control, quality standards and in-house R&D capabilities. PharmaNutra’s business model is anchored in scientific differentiation. The group develops proprietary formulations and technologies, including Sucrosomial® Technology, which is intended to improve nutrient absorption and reduce gastrointestinal side effects, and Cetylated Fatty Acids (CFAs), used in products linked to muscle and joint recovery. The company continues to invest in clinical research and collaborates with Italian and international universities and institutes, supporting a positioning that is more specialised and higher value-added than that of a conventional supplement producer. Its product portfolio is led by brands such as Sideral®, a flagship oral iron line, while the group also relies on other commercial platforms including Cetilar®, which has become increasingly important in sports nutrition. PharmaNutra states that its products are distributed in more than 70 countries, giving the group a meaningful international footprint, although Italy remains a core market in terms of sales and brand recognition. The Pisa industrial base and its nutritional R&D laboratory, presented as one of the most advanced in Europe in the nutraceutical field, provide an important competitive moat through manufacturing integration and scientific credibility. From a competitive standpoint, PharmaNutra stands out through a combination of branded products, proprietary know-how, clinical support and industrial control. Recent reported results point to continued growth in revenue and net profit, with performance improving both in Italy and abroad. A notable recent development is the three-year 2025-2027 sponsorship agreement for Cetilar® Nutrition to become the Official Nutrition Partner of the Giro d’Italia, which should materially support brand visibility in endurance sports. In 2026, published results continued to show solid commercial momentum, while internal dealing disclosures reported to CONSOB remain a standard monitoring point for investors following an Italian mid-cap healthcare name.